Answers are grounded in this paper and cite their sources.
Background Electronic patient-reported outcome (ePRO) monitoring facilitates symptom detection during cancer treatment; however, evidence regarding how pharmacist-led ePRO monitoring is associated with pharmacist practice processes remains limited. This study examined the association of pharmacist-led ePRO monitoring with documented physician–pharmacist collaborations and pharmaceutical interventions during neoadjuvant chemotherapy (NAC) for early-stage breast cancer. Methods This single-center study was a secondary retrospective analysis of the same patient cohort as our previous study and included 96 patients who received NAC for early-stage breast cancer, of whom 43 underwent pharmacist-led ePRO monitoring and 53 received usual care. The primary outcome was the number of documented physician–pharmacist collaborations, and the main secondary outcome was the number of prescription proposals. Adjusted count regression analyses were performed using negative binomial regression for physician–pharmacist collaborations and Poisson regression with robust standard errors for prescription proposals. The number of chemotherapy cycles was incorporated as an offset to account for differences in treatment exposure. Results Among the 96 patients, 43 (44.8%) initiated ePRO monitoring. Among these patients, the median number of ePRO entries during NAC was 74 (IQR, 62–85), and the median reporting completion rate was 71.4% (IQR, 60.1–81.5). Physician–pharmacist collaborations and prescription proposals were more frequent in the ePRO group than in the usual care group (1.53 ± 1.44 vs. 0.38 ± 0.77 and 1.30 ± 1.01 vs. 0.37 ± 0.76, respectively; both p < 0.001). After adjustment for age, ECOG performance status, chemotherapy regimen, and treatment exposure, ePRO monitoring was associated with higher rates of physician–pharmacist collaboration (adjusted incidence rate ratio [IRR], 4.60; 95% CI, 2.45–8.64; p < 0.001) and prescription proposals (adjusted IRR, 3.33; 95% CI, 1.91–5.80; p < 0.001). Conclusions Pharmacist-led ePRO monitoring was associated with higher rates of documented physician–pharmacist collaboration and prescription proposals during NAC for early-stage breast cancer, even after accounting for differences in treatment exposure. These findings suggest that integrating patient-reported symptom monitoring into pharmacist practice may provide additional opportunities for symptom-triggered communication and pharmaceutical intervention. Further prospective studies are needed to determine whether these associations translate into improvements in quality of care or patient outcomes.
No takes yet. Share an insight, caveat, or question.
Takei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: